Smith & Nephew PLC
LSE:SN

Watchlist Manager
Smith & Nephew PLC Logo
Smith & Nephew PLC
LSE:SN
Watchlist
Price: 986 GBX 0.94% Market Closed
Market Cap: 8.6B GBX
Have any thoughts about
Smith & Nephew PLC?
Write Note

Smith & Nephew PLC
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Smith & Nephew PLC
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Smith & Nephew PLC
LSE:SN
Cash from Operating Activities
$733m
CAGR 3-Years
-16%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
LivaNova PLC
NASDAQ:LIVN
Cash from Operating Activities
$158.3m
CAGR 3-Years
14%
CAGR 5-Years
N/A
CAGR 10-Years
8%
EKF Diagnostics Holdings PLC
LSE:EKF
Cash from Operating Activities
ÂŁ11.7m
CAGR 3-Years
10%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Angle PLC
LSE:AGL
Cash from Operating Activities
-ÂŁ12.2m
CAGR 3-Years
-8%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Creo Medical Group PLC
LSE:CREO
Cash from Operating Activities
-ÂŁ20m
CAGR 3-Years
-2%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
B
Belluscura PLC
LSE:BELL
Cash from Operating Activities
-$9.1m
CAGR 3-Years
-84%
CAGR 5-Years
-31%
CAGR 10-Years
N/A
No Stocks Found

Smith & Nephew PLC
Glance View

Market Cap
8.6B GBX
Industry
Health Care

Smith & Nephew PLC, a name synonymous with innovation in the medical technology sphere, began its journey in the late 19th century in the quaint city of Kingston upon Hull, England. This humble pharmaceutical shop evolved over time into a global leader in medical devices, driven by a commitment to improve people's quality of life through pioneering healthcare solutions. Today, the company stands as a key player in three core sectors: orthopedics, advanced wound management, and sports medicine. By focusing on these specialized areas, Smith & Nephew has set itself apart, effectively addressing the complex challenges faced by aging populations and a rising demand for minimally invasive treatments. Revenue streams pour in from their innovative products, which cater to both healthcare professionals and patients worldwide. In orthopedics, they make significant headway with implants and instruments used in hip and knee replacements, essential solutions in addressing joint deterioration and injury. Their advanced wound management division tackles issues from chronic wounds to burns, supplying dressings and delivery systems designed for optimal healing. Meanwhile, the sports medicine segment contributes by offering arthroscopy and enabling technologies, crucial for athletic injury prevention and recovery. By maintaining a strong pipeline of research and development initiatives, Smith & Nephew continues to enhance its offerings, pushing the envelope in medical technology and consequently fortifying its financial foundation.

SN Intrinsic Value
1 474.67 GBX
Undervaluation 33%
Intrinsic Value
Price

See Also

What is Smith & Nephew PLC's Cash from Operating Activities?
Cash from Operating Activities
733m USD

Based on the financial report for Jun 29, 2024, Smith & Nephew PLC's Cash from Operating Activities amounts to 733m USD.

What is Smith & Nephew PLC's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-8%

Over the last year, the Cash from Operating Activities growth was 96%. The average annual Cash from Operating Activities growth rates for Smith & Nephew PLC have been -16% over the past three years , -8% over the past five years .

Back to Top